<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 09, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05613868</url>
  </required_header>
  <id_info>
    <org_study_id>TPN-101-AGS-201</org_study_id>
    <nct_id>NCT05613868</nct_id>
  </id_info>
  <brief_title>TPN-101 in Aicardi-Goutières Syndrome (AGS)</brief_title>
  <official_title>A Phase 2a Study of TPN-101 in Patients With Aicardi-Goutières Syndrome (AGS)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Transposon Therapeutics, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Transposon Therapeutics, Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A phase 2a multi-center, open-label single dose level study of TPN-101 in Patients with&#xD;
      Aicardi-Goutières Syndrome (AGS)&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study is planned in pediatric and adult patients with AGS that are greater than 1 year&#xD;
      and weigh at least 10 kg. The TPN-101 dose will be adjusted from 100 mg to 400 mg based on&#xD;
      weight to achieve similar drug exposures in all subjects. The study plans to enroll 10 - 16&#xD;
      subjects. This study includes a 6-8 week Screening Period, a 48-week Open label Treatment&#xD;
      Period, and a 12-week Follow-up Period.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 15, 2023</start_date>
  <completion_date type="Anticipated">April 2025</completion_date>
  <primary_completion_date type="Anticipated">December 2024</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>open label, single group</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
    <masking_description>Open label study</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Change in innate immune signaling</measure>
    <time_frame>48 weeks</time_frame>
    <description>Assessed by the expression of 30 interferon-stimulated genes (ISG), used to calculate an Interferon (IFN) score in whole blood</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence and severity of spontaneously reported treatment-emergent adverse events (TEAEs) of TPN-101</measure>
    <time_frame>48 weeks</time_frame>
    <description>Incidence and severity of spontaneously reported treatment-emergent adverse events (TEAEs) of TPN-101 administered for up to 48 weeks in patients with AGS</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">16</enrollment>
  <condition>Aicardi-Goutières Syndrome (AGS)</condition>
  <arm_group>
    <arm_group_label>Active, TPN-101</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>100 mg/day to 400mg/ study investigational drug TPN-101 once daily for 48 weeks followed by 12 weeks of follow-up period.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>TPN-101</intervention_name>
    <description>100 mg/ day up to 400mg/day of TPN-101</description>
    <arm_group_label>Active, TPN-101</arm_group_label>
    <other_name>censavudine</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Patients must meet all of the following criteria:&#xD;
&#xD;
        Inclusion&#xD;
&#xD;
          1. Male or female participants of the following ages:&#xD;
&#xD;
               1. Cohort 1: Adults (≥ 18 years of age)&#xD;
&#xD;
               2. Cohort 2: Adolescents (12 to 17 years of age)&#xD;
&#xD;
               3. Cohort 3: Children 5 to 11 years of age&#xD;
&#xD;
               4. Cohort 4: Children 1 to &lt; 5 years of age and &gt;= 10 kg in weight&#xD;
&#xD;
          2. Molecular diagnosis of AGS due to biallelic mutations in 1 of the following 5 genes:&#xD;
             TREX1, RNASEH2A, RNASEH2B, RNASEH2C, or SAMHD1, or due to a recognized dominant&#xD;
             mutation in TREX1&#xD;
&#xD;
          3. IFN score in peripheral blood &gt; 2 standard deviations above the mean score of healthy&#xD;
             controls measured on 3 occasions, approximately 2 weeks apart, during the 6-week&#xD;
             Screening Period.&#xD;
&#xD;
          4. Clinical syndrome consistent with AGS diagnosis based on clinical, CSF, and&#xD;
             radiological findings. The following are examples of such findings (none of these are&#xD;
             required for inclusion):&#xD;
&#xD;
               1. Early onset encephalopathy with psychomotor delay, spasticity, extrapyramidal&#xD;
                  signs, and microcephaly, the latter appearing in the first year of life&#xD;
&#xD;
               2. Calcifications particularly visible at basal ganglia level (putamen, pallidus,&#xD;
                  and thalamus), but also extending to the periventricular white matter&#xD;
&#xD;
               3. Cerebral white matter abnormalities&#xD;
&#xD;
               4. Cerebral atrophy&#xD;
&#xD;
               5. Important systemic symptoms in the early stages of the disease including&#xD;
                  irritability, feeding and sleeping difficulties, unexplained fevers, and the&#xD;
                  appearance of chilblain-like skin lesions on the fingers, toes, and ears&#xD;
&#xD;
          5. Has a reliable caregiver to accompany the patient to all study visits. Caregiver must&#xD;
             have frequent contact with patient and be willing to monitor the patient's health and&#xD;
             concomitant medications throughout the study&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Mutation in IFIH1, ADAR1, LSM11, or RNU7-1.&#xD;
&#xD;
          2. Pre-/perinatal infections, in particular the TORCH complex (toxoplasmosis, rubella,&#xD;
             cytomegalovirus, herpes simplex virus)&#xD;
&#xD;
          3. Presence of other significant neurological disorders; brain tumor or other&#xD;
             space-occupying lesion; history of severe head injury&#xD;
&#xD;
          4. Clinically significant intercurrent illness, medical condition, physical or laboratory&#xD;
             abnormality&#xD;
&#xD;
          5. Autoimmune disease requiring treatment or management (quiescent rheumatoid arthritis,&#xD;
             psoriasis, treated autoimmune thyroiditis, or controlled Type 1 diabetes are&#xD;
             acceptable)&#xD;
&#xD;
          6. History of human immunodeficiency virus (HIV), hepatitis B, or any active infection&#xD;
             during Screening&#xD;
&#xD;
          7. History of cancer within 5 years of Screening, with the exception of fully treated&#xD;
             non-melanoma skin cancers&#xD;
&#xD;
          8. Receipt of an experimental agent within 30 days or 5 half-lives prior to Screening,&#xD;
             whichever is longer&#xD;
&#xD;
          9. Prior treatment with an immunomodulator other than a JAK inhibitor within 6 months of&#xD;
             Screening; patients taking JAK inhibitors for AGS must have been on a stable dose for&#xD;
             one month prior to Screening&#xD;
&#xD;
         10. Current treatment with a nucleoside reverse transcriptase inhibitor (NRTI) or other&#xD;
             antiviral drug&#xD;
&#xD;
         11. Receipt of systemic corticosteroids within 30 days prior to Screening&#xD;
&#xD;
         12. Any vaccination within 30 days prior to Screening&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>12 Months</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Jay Soto</last_name>
    <phone>301-261-5312</phone>
    <email>clinicaltrials@transposonrx.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Laboratory of Neurogenetics and Neuroinflammation Imagine Institute - INSERM U1163</name>
      <address>
        <city>Paris</city>
        <zip>75015</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marie-Louise Frémond</last_name>
    </contact>
    <investigator>
      <last_name>Marie-Louise Frémond</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Presidio Ospedale dei Bambini [Children's Hospital]</name>
      <address>
        <city>Brescia</city>
        <zip>25123</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Elisa Maria Fazzi</last_name>
    </contact>
    <investigator>
      <last_name>Elisa Maria Fazzi</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>SST Fatebenefratelli Sacco</name>
      <address>
        <city>Milano</city>
        <zip>20154</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Davide Tonduti</last_name>
    </contact>
    <investigator>
      <last_name>Davide Tonduti</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Istituto Neurologico Casimiro Mondino</name>
      <address>
        <city>Pavia</city>
        <zip>27100</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Simona Orcesi</last_name>
    </contact>
    <investigator>
      <last_name>Simona Orcesi</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Royal Hospital for Children and Young People</name>
      <address>
        <city>Edinburgh</city>
        <zip>EH9 1LF</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Jayakara Shetty</last_name>
    </contact>
    <investigator>
      <last_name>Jayakara Shetty</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
    <country>Italy</country>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>March 2023</verification_date>
  <study_first_submitted>November 7, 2022</study_first_submitted>
  <study_first_submitted_qc>November 10, 2022</study_first_submitted_qc>
  <study_first_posted type="Actual">November 14, 2022</study_first_posted>
  <last_update_submitted>March 28, 2023</last_update_submitted>
  <last_update_submitted_qc>March 28, 2023</last_update_submitted_qc>
  <last_update_posted type="Actual">March 31, 2023</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>AGS</keyword>
  <keyword>TPN-101</keyword>
  <keyword>censavudine</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Nervous System Malformations</mesh_term>
    <mesh_term>Autoimmune Diseases of the Nervous System</mesh_term>
    <mesh_term>Syndrome</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

